Trial Profile

A Phase 3 trial evaluating Pentarlandir effectiveness against both COVID-19 and influenza

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 19 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pentarlandir (Primary)
Indications COVID 2019 infections; Influenza virus infections
Focus Therapeutic Use
Sponsors SyneuRx International (Taiwan) corp

Most Recent Events

13 Apr 2022 According to SyneuRx media release, Phase 3 trial evaluating effectiveness against both COVID-19 and influenza is expected in the coming months
03 Dec 2021 New trial record
19 Nov 2021 According to SyneuRx media release, the company plans to start this trial in 2022

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com